LifeStance Health Group, Inc. (NASDAQ:LFST) Insider Sells $470,564.29 in Stock (2024)

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) insider Kevin Michael Mullins sold 85,093 shares of the stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $5.53, for a total transaction of $470,564.29. Following the completion of the sale, the insider now owns 4,650,571 shares of the company's stock, valued at approximately $25,717,657.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Get LFST alerts:

LifeStance Health Group Price Performance

Shares of NASDAQ LFST traded down $0.05 during midday trading on Thursday, reaching $5.42. 1,026,382 shares of the company traded hands, compared to its average volume of 1,460,839. The stock's 50-day simple moving average is $6.22 and its 200-day simple moving average is $6.61. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.18 and a current ratio of 1.18. LifeStance Health Group, Inc. has a 12 month low of $4.74 and a 12 month high of $9.59. The firm has a market cap of $2.07 billion, a PE ratio of -11.40 and a beta of 1.23.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. The firm had revenue of $300.44 million during the quarter, compared to the consensus estimate of $299.02 million. LifeStance Health Group had a negative net margin of 15.69% and a negative return on equity of 11.92%. The firm's quarterly revenue was up 18.9% on a year-over-year basis. During the same period last year, the firm posted ($0.09) EPS. As a group, equities analysts anticipate that LifeStance Health Group, Inc. will post -0.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LifeStance Health Group

A number of large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its stake in LifeStance Health Group by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 744,617 shares of the company's stock worth $5,830,000 after purchasing an additional 5,112 shares in the last quarter. FMR LLC lifted its position in LifeStance Health Group by 6.7% during the 3rd quarter. FMR LLC now owns 28,178,666 shares of the company's stock worth $193,587,000 after buying an additional 1,758,427 shares in the last quarter. Principal Financial Group Inc. grew its holdings in LifeStance Health Group by 2.8% during the 4th quarter. Principal Financial Group Inc. now owns 4,006,344 shares of the company's stock worth $31,370,000 after acquiring an additional 110,457 shares during the last quarter. Brown Advisory Inc. increased its position in LifeStance Health Group by 25.9% in the 4th quarter. Brown Advisory Inc. now owns 5,158,980 shares of the company's stock valued at $40,395,000 after acquiring an additional 1,062,887 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of LifeStance Health Group by 21.6% in the fourth quarter. Assetmark Inc. now owns 11,895 shares of the company's stock worth $93,000 after acquiring an additional 2,114 shares during the last quarter. 85.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on LFST shares. The Goldman Sachs Group boosted their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company a "neutral" rating in a research report on Monday, March 4th. Jefferies Financial Group boosted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, March 6th. Morgan Stanley reaffirmed an "overweight" rating and set a $10.00 price objective on shares of LifeStance Health Group in a report on Monday, April 22nd. Finally, Barclays upped their target price on shares of LifeStance Health Group from $7.00 to $8.00 and gave the company an "underweight" rating in a research note on Thursday, February 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $8.80.

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

Should you invest $1,000 in LifeStance Health Group right now?

Before you consider LifeStance Health Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.

While LifeStance Health Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report